This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.

Inclusion Criteria:

• Subject signed inform consent
• Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung
• Pre-operative criteria
• Lung nodule suspicious for NSCLC
• Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen
• Clinical stage I or Clinical stage II
• Not pregnant or nursing
• Negative pregnancy test in premenopausal women
• Fertile patients must use effective contraception
• More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer

Exclusion Criteria:

-